Traders should watch for downward pressure on VERA shares and monitor upcoming filings for any changes in guidance, clinical trial updates, or financing activities. The coordinated nature of these sales by top executives may signal lack of confidence in near-term prospects despite no public negative news.
VERA drugs
VERA drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 23 $42.06entry
- T+1 · 9mo ago +0.74%α +0.00% · $42.37
- T+5 · 9mo ago −3.90%α −4.52% · $40.42
- T+20 · 8mo ago −3.16%α +0.78% · $40.73
- T+60 · 6mo ago −18.33%α −26.58% · $34.35
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Seven executives at Vera Therapeutics, including the CEO, CFO, and other C-suite officers, collectively sold over $1.4 million in shares on February 23, 2026, in coordinated open-market transactions at approximately $42 per share. This represents a significant insider selling cluster involving nearly the entire executive leadership team.
Key Financial Metrics
Key Facts
- CEO Marshall Fordyce sold 16,925 shares for $710,577, the largest individual transaction.
- All seven transactions were open-market sales (Form 4 code 'S') executed on the same day at the same price ($41.9839).
- Total value of the cluster: $1,406,042.71 across 33,490 shares.
- Sellers include CMO, CFO, COO, CCO, CAO, CRO, and CEO, all key executives with direct insight into company performance.
- No purchases or non-cash transactions (e.g., grants, exercises) were part of this cluster.
Financial Impact
$1.41 million in insider selling over a single day
Risk Factors
- Potential perception of insider pessimism ahead of upcoming clinical or financial results.
- Increased selling pressure if additional insiders follow suit or if the company announces equity financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (7 trades, 7d window) | cluster-VERA-1772103657760 |
Track record
25 reports on VERA
12 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +36.47% at T+20 after the Jun 2, 2026 report. 13 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $27.55 Now $26.97 −2.11% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.15 Now $26.97 −4.19% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.15 Now $26.97 −4.19% settles Nov 23
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $30.03 Now $26.97 −10.19% settles Nov 17
- Nov 5, 202611d ago 8-K Bullish 6/10 No price data
- Nov 5, 202611d ago Press Release Bullish 6/10 Entry $29.79 to $28.10 Now $26.97 −9.45% ▼ −5.66% −8.25% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.97 to $30.48 Now $26.97 −15.64% ▼ −4.66% −3.75% vs SPY
- Oct 22, 202625d ago Press Release Bullish 8/10 Entry $29.05 to $30.53 Now $26.97 −7.16% ▲ +5.09% +4.39% vs SPY
- Sep 15, 20268w ago 8-K Bullish 8/10 Entry $33.67 to $34.00 Now $26.97 −19.90% ▲ +0.98% +0.16% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers